NXC680
/ Nextgen Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 26, 2023
Nextgen’s idiopathic pulmonary fibrosis treatment, designated as an orphan drug by the US FDA [Google translation]
(docdocdoc.co.kr)
- "Nextgen Bioscience...announced on the 26th that the U.S. Food and Drug Administration (FDA) has designated 'NXC680', a drug candidate for idiopathic pulmonary fibrosis (IPF), as an Orphan Drug Designation (ODD)....Nextgen plans to apply for an IND (clinical trial protocol) for domestic phase 1 clinical trial of NXC680 in the second quarter of this year, and is planning to accelerate discussions on business development from various angles for global technology transfer of NXC680."
IND • Orphan drug • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease
1 to 1
Of
1
Go to page
1